See more : BlueSword Intelligent Technology Co.,Ltd. (688557.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Gilead Sciences, Inc. (GILD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Gilead Sciences, Inc., a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
You may be interested
- Strategic Energy Resources Limited (SER.AX) Income Statement Analysis – Financial Results
- Chanson International Holding (CHSN) Income Statement Analysis – Financial Results
- Cscec Scimee Sci.&Tech. Co.,Ltd (300425.SZ) Income Statement Analysis – Financial Results
- Digital China Holdings Limited (0861.HK) Income Statement Analysis – Financial Results
- Astro-century Education&Technology Co.,Ltd (300654.SZ) Income Statement Analysis – Financial Results
Gilead Sciences, Inc. (GILD)
About Gilead Sciences, Inc.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1992 | 1991 | 1990 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 27.12B | 27.28B | 27.31B | 24.69B | 22.45B | 22.13B | 26.11B | 30.39B | 32.64B | 24.89B | 11.20B | 9.70B | 8.39B | 7.95B | 7.01B | 5.34B | 4.23B | 3.03B | 2.03B | 1.32B | 867.86M | 466.79M | 233.77M | 195.56M | 169.00M | 32.60M | 40.00M | 33.40M | 2.70M | 4.10M | 4.20M | 2.80M | 1.30M |
| Cost of Revenue | 6.50B | 5.66B | 6.60B | 4.57B | 4.68B | 4.85B | 4.37B | 4.26B | 4.01B | 3.79B | 2.86B | 2.47B | 2.12B | 1.87B | 1.60B | 1.13B | 768.77M | 433.32M | 260.33M | 166.59M | 112.69M | 69.72M | 43.76M | 21.50M | 16.90M | -2.20M | -1.80M | -3.60M | -3.20M | -2.80M | -1.70M | -1.00M | -800.00K |
| Gross Profit | 20.62B | 21.62B | 20.70B | 20.12B | 17.77B | 17.27B | 21.74B | 26.13B | 28.63B | 21.10B | 8.34B | 7.23B | 6.26B | 6.08B | 5.42B | 4.21B | 3.46B | 2.59B | 1.77B | 1.16B | 755.17M | 397.07M | 190.01M | 174.05M | 152.10M | 34.80M | 41.80M | 37.00M | 5.90M | 6.90M | 5.90M | 3.80M | 2.10M |
| Gross Profit Ratio | 76.04% | 79.26% | 75.82% | 81.48% | 79.18% | 78.07% | 83.26% | 85.98% | 87.73% | 84.78% | 74.48% | 74.53% | 74.67% | 76.48% | 77.24% | 78.87% | 81.83% | 85.68% | 87.17% | 87.42% | 87.02% | 85.06% | 81.28% | 89.00% | 90.00% | 106.75% | 104.50% | 110.78% | 218.52% | 168.29% | 140.48% | 135.71% | 161.54% |
| Research & Development | 6.92B | 4.98B | 5.36B | 5.04B | 9.11B | 5.02B | 3.73B | 5.10B | 3.01B | 2.85B | 2.12B | 1.76B | 1.23B | 1.07B | 939.92M | 721.77M | 591.03M | 383.86M | 277.72M | 223.55M | 164.87M | 134.76M | 185.55M | 131.57M | 112.90M | 75.30M | 59.20M | 41.90M | 0.00 | 26.00M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 5.26B | 4.90B | 4.51B | 4.36B | 3.60B | 4.06B | 3.88B | 3.40B | 3.43B | 2.98B | 1.70B | 1.46B | 1.24B | 1.04B | 946.69M | 797.34M | 705.74M | 573.66M | 379.25M | 302.79M | 250.16M | 181.30M | 125.14M | 82.79M | 78.30M | 31.00M | 25.50M | 26.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 826.00M | 778.00M | 735.00M | 795.00M | 784.00M | 587.00M | 600.00M | 618.00M | 601.00M | 393.00M | 216.00M | 160.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.09B | 5.67B | 5.25B | 5.15B | 4.38B | 4.06B | 3.88B | 3.40B | 3.43B | 2.98B | 1.70B | 1.46B | 1.24B | 1.04B | 946.69M | 797.34M | 705.74M | 573.66M | 379.25M | 302.79M | 250.16M | 181.30M | 125.14M | 82.79M | 78.30M | 31.00M | 25.50M | 26.70M | 34.70M | 7.60M | 22.40M | 9.10M | 6.10M |
| Other Expenses | 0.00 | -581.00M | -639.00M | -1.42B | 1.87B | 676.00M | 523.00M | 428.00M | 154.00M | 3.00M | -8.89M | -37.28M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.22M | 0.00 | 0.00 | 12.01M | 12.60M | 2.80M | 3.00M | 4.50M | 3.20M | 2.80M | 1.70M | 1.00M | 800.00K |
| Operating Expenses | 13.67B | 10.65B | 10.61B | 10.19B | 13.49B | 9.07B | 7.61B | 8.50B | 6.44B | 5.84B | 3.82B | 3.22B | 2.47B | 2.12B | 1.89B | 1.53B | 1.30B | 957.52M | 656.97M | 526.35M | 425.25M | 316.06M | 310.69M | 226.37M | 203.80M | 109.10M | 87.70M | 73.10M | 37.90M | 36.40M | 24.10M | 10.10M | 6.90M |
| Cost & Expenses | 19.69B | 16.31B | 17.21B | 14.76B | 18.16B | 13.93B | 11.98B | 12.76B | 10.45B | 9.63B | 6.68B | 5.69B | 4.60B | 3.99B | 3.48B | 2.66B | 2.07B | 1.39B | 917.30M | 692.93M | 537.94M | 385.78M | 354.46M | 247.87M | 220.70M | 106.90M | 85.90M | 69.50M | 34.70M | 33.60M | 22.40M | 9.10M | 6.10M |
| Interest Income | 0.00 | 935.00M | 1.00B | 984.00M | 995.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 66.58M | 60.29M | 42.40M | 59.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 944.00M | 935.00M | 1.00B | 984.00M | 995.00M | 1.08B | 1.12B | 964.00M | 688.00M | 412.00M | 306.89M | 360.92M | 205.42M | 108.96M | 69.66M | 12.10M | 0.00 | 4.67B | 0.00 | 0.00 | 996.28M | 23.66M | 0.00 | 6.12M | 37.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.69B | 2.10B | 2.05B | 1.48B | 1.40B | 1.43B | 1.29B | 1.16B | 1.10B | 1.05B | 344.70M | 278.21M | 302.23M | 265.48M | 212.94M | 102.47M | 51.28M | 47.28M | 35.78M | 24.41M | 20.86M | 14.43M | 14.69M | 12.01M | 12.60M | 2.80M | 3.00M | 4.50M | 3.20M | 2.80M | 1.70M | 1.00M | 800.00K |
| EBITDA | 10.50B | 8.85B | 11.33B | 4.13B | 7.56B | 10.31B | 15.93B | 19.22B | 23.45B | 16.32B | 4.86B | 4.25B | 4.16B | 4.29B | 3.78B | 2.84B | 2.22B | -576.83M | 1.15B | 688.18M | 350.78M | 81.01M | -106.00M | -40.31M | -39.10M | -65.10M | -56.90M | -31.60M | -28.80M | -31.30M | -16.50M | -5.30M | -4.00M |
| EBITDA Ratio | 38.71% | 38.10% | 34.63% | 34.46% | 27.42% | 40.11% | 56.10% | 59.43% | 68.47% | 61.34% | 40.31% | 40.95% | 45.99% | 50.60% | 50.94% | 51.47% | 52.38% | 134.71% | 56.54% | 48.54% | 97.90% | 23.88% | -116.58% | -19.15% | -9.05% | -275.77% | -153.00% | -139.52% | -1,259.26% | -753.66% | -495.24% | -257.14% | -369.23% |
| Operating Income | 7.61B | 7.33B | 7.41B | 7.03B | 4.29B | 8.20B | 14.12B | 17.63B | 22.19B | 15.27B | 4.52B | 4.01B | 3.79B | 3.96B | 3.53B | 2.68B | 2.16B | -758.75M | 1.11B | 631.69M | -158.68M | 81.01M | -120.69M | -52.32M | -51.70M | -74.30M | -45.90M | -36.10M | -32.00M | -29.50M | -18.20M | -6.30M | -4.80M |
| Operating Income Ratio | 28.05% | 26.87% | 27.12% | 28.47% | 19.10% | 37.06% | 54.10% | 58.02% | 68.00% | 61.33% | 40.39% | 41.33% | 45.20% | 49.84% | 50.34% | 50.20% | 51.17% | -25.07% | 54.78% | 47.69% | -18.28% | 17.35% | -51.63% | -26.75% | -30.59% | -227.91% | -114.75% | -108.08% | -1,185.19% | -719.51% | -433.33% | -225.00% | -369.23% |
| Total Other Income/Expenses | -746.00M | -1.52B | 872.00M | -2.40B | 873.00M | -401.00M | -595.00M | -536.00M | -534.00M | -409.00M | -315.78M | -398.20M | -138.84M | -48.67M | -27.27M | -5.84M | 105.83M | 120.55M | 50.69M | 24.73M | -8.86M | -7.61M | 178.14M | 10.41M | -13.90M | 22.40M | -500.00K | 15.00M | 5.20M | 9.90M | 4.30M | 1.90M | 800.00K |
| Income Before Tax | 6.86B | 5.81B | 8.28B | 1.67B | 5.16B | 7.80B | 13.53B | 17.10B | 21.66B | 14.86B | 4.21B | 3.61B | 3.65B | 3.91B | 3.50B | 2.73B | 2.27B | -638.21M | 1.16B | 656.42M | -167.53M | 73.40M | 57.45M | -41.91M | -65.60M | -55.90M | -27.60M | -21.10M | -26.80M | -25.30M | -13.90M | -4.40M | -4.00M |
| Income Before Tax Ratio | 25.30% | 21.31% | 30.32% | 6.76% | 22.99% | 35.25% | 51.82% | 56.26% | 66.36% | 59.69% | 37.57% | 37.23% | 43.54% | 49.23% | 49.95% | 51.25% | 53.67% | -21.09% | 57.28% | 49.56% | -19.30% | 15.72% | 24.57% | -21.43% | -38.82% | -171.47% | -69.00% | -63.17% | -992.59% | -617.07% | -330.95% | -157.14% | -307.69% |
| Income Tax Expense | 1.25B | 1.25B | 2.08B | 1.58B | -204.00M | 2.34B | 8.89B | 3.61B | 3.55B | 2.80B | 1.15B | 1.04B | 861.95M | 1.02B | 876.36M | 723.25M | 655.04M | 551.75M | 347.88M | 207.05M | -95.53M | 1.30M | 4.14M | 1.20M | 900.00K | -36.60M | -36.20M | -29.40M | -9.80M | -8.00M | -8.40M | -3.70M | -1.60M |
| Net Income | 5.67B | 4.59B | 6.23B | 89.00M | 5.39B | 5.46B | 4.63B | 13.50B | 18.11B | 12.10B | 3.07B | 2.59B | 2.80B | 2.90B | 2.64B | 2.01B | 1.62B | -1.19B | 813.91M | 449.37M | -72.00M | 72.10M | 52.27M | -56.78M | -66.50M | -56.10M | -28.00M | -21.70M | -27.40M | -25.70M | -14.10M | -4.50M | -4.00M |
| Net Income Ratio | 20.89% | 16.83% | 22.80% | 0.36% | 23.99% | 24.65% | 17.73% | 44.43% | 55.48% | 48.62% | 27.45% | 26.71% | 33.43% | 36.50% | 37.59% | 37.69% | 38.19% | -39.32% | 40.13% | 33.92% | -8.30% | 15.45% | 22.36% | -29.03% | -39.35% | -172.09% | -70.00% | -64.97% | -1,014.81% | -626.83% | -335.71% | -160.71% | -307.69% |
| EPS | 4.54 | 3.66 | 4.96 | 0.07 | 4.24 | 4.20 | 3.54 | 10.08 | 12.37 | 7.95 | 2.01 | 1.71 | 1.81 | 1.70 | 1.46 | 1.09 | 0.87 | -0.65 | 0.45 | 0.26 | -0.04 | 0.05 | 0.04 | -0.04 | -0.05 | -0.04 | -0.03 | -0.02 | -0.04 | -0.04 | -0.03 | -0.01 | -0.01 |
| EPS Diluted | 4.50 | 3.64 | 4.93 | 0.07 | 4.22 | 4.17 | 3.51 | 9.94 | 11.91 | 7.35 | 1.81 | 1.64 | 1.78 | 1.66 | 1.41 | 1.05 | 0.84 | -0.65 | 0.43 | 0.25 | -0.04 | 0.04 | 0.03 | -0.04 | -0.05 | -0.04 | -0.03 | -0.02 | -0.04 | -0.04 | -0.03 | -0.01 | -0.01 |
| Weighted Avg Shares Out | 1.25B | 1.26B | 1.26B | 1.26B | 1.27B | 1.30B | 1.31B | 1.34B | 1.46B | 1.52B | 1.53B | 1.51B | 1.55B | 1.71B | 1.81B | 1.84B | 1.86B | 1.84B | 1.82B | 1.73B | 1.61B | 1.56B | 1.52B | 1.46B | 1.37B | 1.31B | 1.04B | 889.15M | 680.77M | 595.94M | 512.73M | 360.00M | 304.76M |
| Weighted Avg Shares Out (Dil) | 1.26B | 1.26B | 1.26B | 1.26B | 1.28B | 1.31B | 1.32B | 1.36B | 1.52B | 1.65B | 1.69B | 1.58B | 1.58B | 1.75B | 1.87B | 1.92B | 1.93B | 1.84B | 1.90B | 1.86B | 1.61B | 1.65B | 1.62B | 1.46B | 1.37B | 1.31B | 1.04B | 889.15M | 680.77M | 595.94M | 512.73M | 360.00M | 304.76M |
Gilead Signs Royalty-Free Voluntary Licensing Agreements With Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has signed non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical manufacturers to make and sell generic lenacapavir, subject to required regulatory approvals, in 120 high-incidence, resource-limited countries, which...
Gilead Sciences (GILD) Increases Despite Market Slip: Here's What You Need to Know
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $83.94, denoting a +0.12% change from the preceding trading day.
2 Top Picks With Contrarian Potential as Q4 Looms
Subscribers to Chart of the Week received this commentary on Sunday, September 29.
Gilead Sciences (GILD) Stock Slides as Market Rises: Facts to Know Before You Trade
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $83.79, denoting a -0.24% change from the preceding trading day.
Top 4 Health Care Stocks That May Keep You Up At Night
As of Sept. 24, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
3 Dirt Cheap Stocks to Buy Right Now
CRISPR Therapeutics is still in its early stages of growth. Gilead Sciences remains an underrated stock.
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Gilead Sciences stock nears its all-time high: buy or sell?
Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million settlement with American authorities. It has risen for two consecutive weeks, reaching a high of $84, its highest point...
Gilead Sciences (GILD) Stock Sinks As Market Gains: Here's Why
The latest trading day saw Gilead Sciences (GILD) settling at $83.08, representing a -0.1% change from its previous close.
Source: https://incomestatements.info
Category: Stock Reports